http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2323221-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c90d4c9eb6f4837513dd1a4c6906f811 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b98606d9cda02a2861481483e9fe4b8 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5365 |
| filingDate | 2006-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2008-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d404b8e14c73c94ed625a68e6dcff823 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da5727719479563e00587dfe1f31c7b9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d3eb14c9ab8287f65f8f2ce549583e1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e3a5c695e75ca9798b951a67abc097f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d60bb4c40db7bea38366a58607675689 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9d6475b65e0a12129b2f9e53a50c016 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f44160696dd1e7990b09dc5ec43251ab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7399850d24a538f75d6bb80bad34606 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb11515f7708e2be9621f5f8c6c0ea6d |
| publicationDate | 2008-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2323221-C2 |
| titleOfInvention | SUBSTITUTED ESTERS OF 1,2,3,7-TETRAHYDROPYRROLO[3,2-f][1,3]BENZOXAZIN-5-CARBOXYLIC ACIDS, PHARMACEUTICAL COMPOSITION, METHOD FOR THEIR PREPARING (VARIANTS) AND USING |
| abstract | FIELD: organic chemistry, medicine, pharmacy, chemical technology. n SUBSTANCE: invention relates to novel substituted esters of 1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazin-5-carboxylic acids of the general formula (1): or their racemates, or their optical isomers, or their pharmaceutically acceptable salts and/or hydrates possessing the antiviral effect. In compounds of the general formula (1) each R 1 and R 4 represents independently of one another a substitutes of amino group chosen from hydrogen atom, optionally substituted linear or branched alkyl comprising 3-12 carbon atoms, optionally substituted cycloalkyl comprising 3-10 carbon atoms, optionally substituted aryl or optionally substituted and possibly an annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides; R 2 represents alkyl substitute chosen from hydrogen atom, optionally substituted mercapto group, optionally substituted amino group, optionally substituted hydroxyl; R 3 represents lower alkyl or cycloalkyl; R 5 represents a substitute of cyclic system chosen from hydrogen atom, optionally substituted linear or branched alkyl comprising 3-12 carbon atoms, optionally substituted cycloalkyl comprising 3-10 carbon atoms, optionally substituted aryl or optionally substituted and optionally an annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides; R 6 represents a substitute of cyclic system chosen from hydrogen atom, halogen atom, cyano group, optionally substituted aryl or optionally substituted and optionally annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides. Also, invention relates to methods for treatment, drugs and pharmaceutical compositions using compounds of this invention. Proposed compounds can be used as active components of drugs used in treatment of such diseases as infectious hepatitis, human immunodeficiency, atypical pneumonia and avian influenza. n EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved methods of synthesis. n 22 cl, 3 tbl, 6 dwg, 7 ex |
| priorityDate | 2006-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 57.